Impact of high glucose on sorafenib resistance in HepG2 cell lines

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with many hurdles on the sides of early diagnosis and proper treatment. Sorafenib is an FDA approved chemotherapeutic against hepatocellular carcinoma, yet with drawbacks including daunting chemoresistance and a recurrence after remission. The interplay between sorafenib and high glucose status is widely debated. Moreover, understanding the impact of high glucose status in the literature is wanting since its osmotic impact has always been omitted. This present study was conducted at Medical Biochemistry department, Faculty of Medicine, Ain Shams University, from summer 2020 to spring 2021. Utilizing HepG2 cell lines, the study aimed at exploring the impact of high glucose status in the existence of sorafenib. The outcome was represented cellularly by measuring the cellular viability and molecularly by the assessment of MALAT1 and H19 RQs. The impact of high glucose status was subdivided into two major parts: the metabolic and the osmotic impact, therefore mannitol was utilized as a negative osmotic control for the potential osmotic effect of high glucose status.